98 results on '"Mitlak, Bruce"'
Search Results
2. Phase 1b Evaluation of Abaloparatide Solid Microstructured Transdermal System (Abaloparatide-sMTS) in Postmenopausal Women with Low Bone Mineral Density
3. Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
4. Abaloparatide improves cortical geometry and trabecular microarchitecture and increases vertebral and femoral neck strength in a rat model of male osteoporosis
5. Abaloparatide, a novel osteoanabolic PTHrP analog, increases cortical and trabecular bone mass and architecture in orchiectomized rats by increasing bone formation without increasing bone resorption
6. Response rates for lumbar spine, total hip, and femoral neck bone mineral density in men treated with abaloparatide: results from the ATOM study.
7. Abaloparatide followed by alendronate in women ≥80 years with osteoporosis: post hoc analysis of ACTIVExtend
8. Efficacy and Safety of Transdermal Abaloparatide in Postmenopausal Women with Osteoporosis: A Randomized Study.
9. Effect of Abaloparatide on Bone Microarchitecture Assessed by Trabecular Bone Score in Women With Osteoporosis: Post Hoc Analysis of ACTIVE and ACTIVExtend.
10. Does Teriparatide Improve Femoral Neck Fracture Healing: Results From A Randomized Placebo-controlled Trial
11. The Efficacy and Safety of Abaloparatide‐SC in Men With Osteoporosis: A Randomized Clinical Trial.
12. Femoral strength in osteoporotic women treated with teriparatide or alendronate
13. Clinical evaluation of medicinal products for acceleration of fracture healing in patients with osteoporosis
14. Recommendations for an update of the current (2001) regulatory requirements for registration of drugs to be used in the treatment of osteoporosis in postmenopausal women and in men
15. Validation of the Surrogate Threshold Effect for Change in Bone Mineral Density as a Surrogate Endpoint for Fracture Outcomes: The FNIH‐ASBMR SABRE Project.
16. Selective Estrogen Receptor Modulators: A Look Ahead
17. Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis
18. Teriparatide and Raloxifene Reduce the Risk of New Adjacent Vertebral Fractures in Postmenopausal Women with Osteoporosis: Results from Two Randomized Controlled Trials
19. Critical Issues in Translational and Clinical Research for the Study of New Technologies to Enhance Bone Repair
20. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women
21. ENHANCEMENT OF EXPERIMENTAL FRACTURE-HEALING BY SYSTEMIC ADMINISTRATION OF RECOMBINANT HUMAN PARATHYROID HORMONE (PTH 1–34)
22. Sustained Vertebral Fracture Risk Reduction After Withdrawal of Teriparatide in Postmenopausal Women With Osteoporosis
23. Pharmacogenomics in Endocrinology
24. Long-term Effects of Raloxifene on Bone Mineral Density, Bone Turnover, and Serum Lipid Levels in Early Postmenopausal Women: Three-Year Data From 2 Double-blind, Randomized, Placebo-Controlled Trials
25. Early Effects of Abaloparatide on Bone Formation and Resorption Indices in Postmenopausal Women With Osteoporosis.
26. Reduction of Vertebral Fracture Risk in Postmenopausal Women With Osteoporosis Treated With Raloxifene: Results From a 3-Year Randomized Clinical Trial
27. Update in Endocrinology
28. Parathyroid hormone as a therapeutic agent
29. Treatment‐Related Changes in Bone Turnover and Fracture Risk Reduction in Clinical Trials of Antiresorptive Drugs: Proportion of Treatment Effect Explained.
30. Cardiovascular Safety of Abaloparatide in Postmenopausal Women With Osteoporosis: Analysis From the ACTIVE Phase 3 Trial.
31. Abaloparatide: an anabolic treatment to reduce fracture risk in postmenopausal women with osteoporosis.
32. Abaloparatide in Postmenopausal Women With Osteoporosis and Type 2 Diabetes: A Post Hoc Analysis of the ACTIVE Study.
33. Abaloparatide in patients with mild or moderate renal impairment: results from the ACTIVE phase 3 trial.
34. Recommendations for the conduct of clinical trials for drugs to treat or prevent sarcopenia.
35. The Effect of Discontinuing Treatment With Blosozumab: Follow-up Results of a Phase 2 Randomized Clinical Trial in Postmenopausal Women With Low Bone Mineral Density.
36. Quality of Life in Sarcopenia and Frailty.
37. Is Diabetes Mellitus a Heart Disease Equivalent in Women?: Results From an International Study of Postmenopausal Women in the Raloxifene Use for the Heart (RUTH) Trial.
38. Long-term raloxifene for postmenopausal osteoporosis.
39. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women.
40. Teriparatide for Acceleration of Fracture Repair in Humans: A Prospective, Randomized, Double-Blind Study of 102 Postmenopausal Women With Distal Radial Fractures.
41. Effects of Teriparatide and Alendronate on Vertebral Strength as Assessed by Finite Element Modeling of QCT Scans in Women With Osteoporosis.
42. Sustained Nonvertebral Fragility Fracture Risk Reduction After Discontinuation of Teriparatide Treatment.
43. Recommendations for the Registration of Agents to be Used in the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis: Updated Recommendations from the Group for the Respect of Ethics and Excellence in Science.
44. Recombinant Human Parathyroid Hormone (1-34) [Teriparatide] Improves Both Cortical and Cancellous Bone Structure.
45. The Skeletal Response to Teriparatide Is Largely Independent of Age, Initial Bone Mineral Density, and Prevalent Vertebral Fractures in Postmenopausal Women With Osteoporosis.
46. Relationships Between Bone Mineral Density and Incident Vertebral Fracture Risk with Raloxifene Therapy.
47. In Search of Optimal Long-Term Female Hormone Replacement: The Potential of Selective Estrogen Receptor Modulators.
48. Sequential effects of chronic human PTH (1-84) treatment of estrogen-deficiency osteopenia in the rat.
49. The effect of systemically administered PDGF-BB on the rodent skeleton.
50. Accuracy, precision, and utility of spine and whole-skeleton mineral measurements by dxa in rats.
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.